BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Illustrations Gained from a Crosscountry Excursion - 2The most effective method to Pick a Campervan That Offers Something else for Less
- 3Must-See Attractions in Australia
- 4A hunger for new experiences Narratives: Motivating Travel and Experience
- 5Most loved VR Game for Wellness: Which Keeps You Dynamic?
- The Delight of Perusing: Book Proposals for Each Class
- Vote in favor of your #1 sort of juice
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- Behind every perfect holiday memory is a mom on the brink
- Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
